Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...